KRAS G13D-IN-1
KRAS G13D-IN-1 (compound 41) is a selective and covalently reversible inhibitor of KRASG13D (IC50: 0.41 nM) . The selectivity for KRASG13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRASG13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades[1].
Product Specifications
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kras-g13d-in-1.html
Solubility
10 mM in DMSO
Smiles
NC1=N[C@@]([C@@]2=C(F)C3=C(C(N4[C@@H](C)CN(C(/C=C/C5=CC=CC6=C5C[N@@]7C[C@H]6CC7)=O)CC4)=NC(OC[C@@]89CCCN8CC(C9)=C)=N3)C=C2Cl)=C(C(F)(F)F)C(C)=C1
Molecular Formula
C43H45ClF4N8O2
Molecular Weight
817.32
References & Citations
[1]Nilewski C, et al. Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors. ACS Med Chem Lett. 2023 Dec 6;15 (1) :21-28.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 8/18 (C-51), CF594 conjugate, 0.1mg/mL
CD81 / TAPA-1 (1.3.3.22), CF740 conjugate, 0.1mg/mL
CD81 / TAPA-1 (1.3.3.22), CF640R conjugate, 0.1mg/mL
